GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Float Percentage Of Total Shares Outstanding

ZyVersa Therapeutics (ZyVersa Therapeutics) Float Percentage Of Total Shares Outstanding : 100.35% (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ZyVersa Therapeutics's float shares is 0.83 Mil. ZyVersa Therapeutics's total shares outstanding is 0.83 Mil. ZyVersa Therapeutics's float percentage of total shares outstanding is 100.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ZyVersa Therapeutics's Insider Ownership is 64.39%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ZyVersa Therapeutics's Institutional Ownership is 0.04%.


ZyVersa Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ZyVersa Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.83/0.83
=100.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Executives
Pablo A. Guzman officer: Chief Medical Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover director, officer: Chief Executive Officer 108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr. officer: Chief Scientific Officer C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe officer: Chief Financial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere officer: Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park director C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd. 10 percent owner 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones director, officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor director, officer: Chief Executive Officer C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp. 10 percent owner 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880

ZyVersa Therapeutics (ZyVersa Therapeutics) Headlines

From GuruFocus